Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/7/2026

1. HUVR:IN
2. ANET
3. NKE
4. PANW
5. CL
6. SNDK
7. TAP
8. DELL
9. ROIV
10. BAC

Go back to Fusion Pharmaceuticals to be Acquired by AstraZeneca, Accelerating Development of Next-Generation Radioconjugates to Treat Cancer

Morgan Stanley Downgrades Fusion Pharmaceuticals (FUSN) to Equalweight

March 19, 2024 2:40 PM EDT

Morgan Stanley analyst Matthew Harrison downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Overweight to Equalweight with a price target of $21.00 (from $10.00).

The analyst comments "Fusion to be acquired by AstraZeneca for $21/share in cash payable at deal closing (vs. 03/18 closing price of $10.64),... More

Jefferies Downgrades Fusion Pharmaceuticals (FUSN) to Hold

March 19, 2024 10:00 AM EDT

Jefferies analyst Suji Jeong downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Buy to Hold with a price target of $21.00 (from $10.00).

The analyst comments "AZN will acquire FUSN's radiopharma platform for $21/sh in cash (~$2B upfront), plus another $3/sh CVR (~$400M value) upon... More